| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-598 | |
| Phytochemical name or plant extracts | Niloticin | |
| PMID | 26320684 | |
| Literature evidence | The antiplasmodial activities of the crude extracts and the isolated constituents against the D6 and W2 strains of Plasmodium falciparum were determined using the semiautomated micro dilution technique that measures the ability of the extracts to inhibit the incorporation of (G-(3)H, where G is guanine) hypoxanthine into the malaria parasite. | |
| IUPAC name | (5R,9R,10R,13S,14S,17S)-17-[(2S,4R)-4-[(2S)-3,3-dimethyloxiran-2-yl]-4-hydroxybutan-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one | |
| Phytochemicals’ class or type of plant extracts | Protolimonoid | |
| Source of phytochemicals or plant Extracts | Turraea nilotica | |
| Geographical availability | Burundi, Ethiopia, Kenya, Malawi, Mozambique, Northern Provinces, Somalia, Sudan, Swaziland, Tanzania, Zambia, Zimbabwe | |
| Plant parts | Stem | |
| Other cancers | Breast cancer, Larynx cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 14.5±0.5 µg/mL against 4T1 | |
| Potency | NA | |
| Cell line/ mice model | 4T1, HEp2, Vero | |
| Additional information | Niloticin is an attractive osteoclastogenesis inhibitor and, therefore, might exert a beneficial effect on bone health. Niloticin has therapeutic potential and binds to MD-2. | |
| PubChem ID | 14021529 | |
| Additional PMIDs | 35364377, 36314579 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:579805-1 | |
| Safety | NA |